Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors

被引：8

作者：

Huang, Mingqi ^{[1
]}

Ren, Jinghui ^{[1
]}

Wang, Yuhong ^{[1
]}

Chen, Xixi ^{[1
]}

Yang, Jia ^{[1
]}

Tang, Tu ^{[1
]}

Yang, Zhenyong ^{[1
]}

Li, Xiaojing ^{[1
]}

Ji, Min ^{[2
]}

Cai, Jin ^{[1
]}

机构：

[1] Southeast Univ, Sch Chem & Chem Engn, Nanjing 211189, Jiangsu, Peoples R China

[2] Southeast Univ, Sch Biol Sci & Med Engn, Nanjing 210096, Peoples R China

来源：

CHEMICAL & PHARMACEUTICAL BULLETIN | 2021年 / 69卷 / 07期

关键词：

poly(ADP-ribose)polymerase 1 (PARP1) inhibitor; phthalazinone; Olaparib; POLY(ADP-RIBOSE);

D O I：

10.1248/cpb.c20-01018

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Poly(ADP-ribose)polymerase (PARP) is a significant therapeutic target for the treatment of numerous human diseases. Olaparib has been approved as a PARP inhibitor. In this paper, a series of new compounds were designed and synthesized with Olaparib as the lead compound. In order to evaluate the inhibitory activities against PARP1 of the synthesized compounds, in vitro PARP1 inhibition assay and intracellular PARylation assay were conducted. The results showed that the inhibitory activities of the derivatives were related to the type of substituent and the length of alkyl chain connecting the aromatic ring. 3-(4,5-Dimethy-12-thiazoly1)-2,5-diphenyl-2H-tetrazolium bromide (MTT)-based assay also proved that these compounds demonstrating strong inhibition to PARP1 also have high anti-proliferative activities against BRCA2-deficient cell line (Capan-1). Analysis of the entire results suggest that compound 23 with desirable inhibitory efficiency may hold promise for further in vivo exploration of PARP inhibition.

引用

页码：620 / 629

页数：10

共 50 条

[41] New applications of PARP inhibitors
不详
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (SUPPL 1) : S17 - S21
[42] On the way to selective PARP-2 inhibitors. Design, synthesis, and prelimionary evaluation of a series of isoquinolinone derivatives
Pellicciari, Roberto
Camaioni, Emidio
Costantino, Gabriele
Formentini, Laura
Sabbatini, Paola
Venturoni, Francesco
Eren, Goekcen
Bellocchi, Daniele
Chiarugi, Alberto
Moroni, Flavio
CHEMMEDCHEM, 2008, 3 (06) : 914 - 923
[43] Design of novel selective PARP inhibitors in search for new neuroprotective agents
不详
PHARMACOLOGICAL REPORTS, 2005, 57 (03) : 425 - 426
[44] Design of new topoisomerase I inhibitors: Synthesis and in vitro activity.
Minchera, DJ
Kaya, G
Pettersson, S
Turnbull, A
Bibby, MC
BRITISH JOURNAL OF CANCER, 2001, 85 : 92 - 92
[45] Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation
Boraei, Ahmed T. A.
Singh, Pankaj K.
Sechi, Mario
Satta, Sandro
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 182
[46] Design, Synthesis, and Evaluation of New Pyrazolines As Small Molecule Inhibitors of Acetylcholinesterase
Altintop, Mehlika Dilek
Ozkan, Begum Nurpelin Saglik
Ozdemir, Ahmet
ACS OMEGA, 2024, 9 (29): : 31401 - 31409
[47] Design, synthesis, and pharmacological evaluation of new farnesyl protein transferase inhibitors
Houssin, R
Pommery, J
Salaün, MC
Deweer, S
Goossens, JF
Chavatte, P
Hénichart, JP
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (02) : 533 - 536
[48] DESIGN, SYNTHESIS AND IN VITRO EVALUATION OF NEW AZAPEPTIDE INHIBITORS OF SERINE PROTEASES
Obreza, A.
Jager, M.
Stegnar, M.
Urleb, U.
JOURNAL OF PEPTIDE SCIENCE, 2004, 10 : 256 - 256
[49] Design, synthesis and in vitro evaluation of new azaphenylalanine serine proteases inhibitors
Obreza, Ales
Jager, Martina
Stegnar, Mojca
Urleb, Uros
PEPTIDES 2004, PROCEEDINGS: BRIDGES BETWEEN DISCIPLINES, 2005, : 914 - 915
[50] Design, synthesis, and preliminary evaluation of new pyrrolidine derivatives as neuraminidase inhibitors
Zhang, Jie
Xu, Wenfang
Liu, Ailin
Du, Guanhua
MEDICINAL CHEMISTRY, 2008, 4 (03) : 206 - 209

← 1 2 3 4 5 →